American Association for Cancer Research
00085472can111714-sup-legends_pdf_68k.pdf (68.65 kB)

Supplementary Figure Legends 1-6 from GLIPR1 Suppresses Prostate Cancer Development through Targeted Oncoprotein Destruction

Download (68.65 kB)
journal contribution
posted on 2023-03-30, 20:53 authored by Likun Li, Chengzhen Ren, Guang Yang, Elmoataz Abdel Fattah, Alexei A. Goltsov, Soo Mi Kim, Ju-Seog Lee, Sanghee Park, Francesco J. Demayo, Michael M. Ittmann, Patricia Troncoso, Timothy C. Thompson

PDF file - 68K



Downregulation of the proapoptotic p53 target gene glioma pathogenesis-related protein 1 (GLIPR1) occurs frequently in prostate cancer, but the functional meaning of this event is obscure. Here, we report the discovery of functional relationship between GLIPR1 and c-Myc in prostate cancer where c-Myc is often upregulated. We found that the expression of GLIPR1 and c-Myc were inversely correlated in human prostate cancer. Restoration of GLIPR1 expression in prostate cancer cells downregulated c-myc levels, inhibiting cell-cycle progression. Downregulation was linked to a reduction in β-catenin/TCF4-mediated transcription of the c-myc gene, which was caused by GLIPR1-mediated redistribution of casein kinase 1α (CK1α) from the Golgi apparatus to the cytoplasm where CK1α could phosphorylate β-catenin and mediate its destruction. In parallel, GLIPR1 also promoted c-Myc protein ubiquitination and degradation by glycogen synthase kinase-3α- and/or CK1α-mediated c-Myc phosphorylation. Notably, genetic ablation of the mouse homolog of Glipr1 cooperated with c-myc overexpression to induce prostatic intraepithelial neoplasia and prostate cancer. Together, our findings provide evidence for CK1α-mediated destruction of c-Myc and identify c-Myc S252 as a crucial CK1α phosphorylation site for c-Myc degradation. Furthermore, they reveal parallel mechanisms of c-myc downregulation by GLIPR1 that when ablated in the prostate are sufficient to drive c-Myc expression and malignant development. Cancer Res; 71(24); 7694–704. ©2011 AACR.

Usage metrics

    Cancer Research




    Ref. manager